Company Overview

Biofrontera Inc. is a U.S.-based biopharmaceutical company focused on the commercialization of dermatological products, particularly therapies used in the treatment of non-melanoma skin cancers and chronic skin conditions. The company operates within the dermatology and oncology-supportive healthcare sectors and is publicly traded on Nasdaq under the ticker BFRI. Its primary revenue driver is the commercialization of prescription photodynamic therapy products and related medical devices used by dermatologists in outpatient clinical settings. The company’s core commercial products include Ameluz® (aminolevulinic acid hydrochloride gel), a prescription drug used with photodynamic therapy for actinic keratosis, and the BF-RhodoLED® lamp platform used to activate the therapy.

Biofrontera Inc. was established as the U.S. commercial entity associated with Germany-based Biofrontera AG and later became an independent publicly listed company in the United States. The company evolved from a distribution and commercialization model centered on licensed dermatology products into a broader dermatology-focused commercial platform. Its strategic positioning is tied to physician-focused sales infrastructure, specialization in photodynamic therapy, and regulatory-approved dermatologic therapies that address high-incidence skin conditions associated with aging populations and sun exposure.

Business Operations

Biofrontera Inc. generates revenue primarily through sales of prescription dermatology therapies and medical devices in the United States. Its operating activities are concentrated in the commercialization of Ameluz® and the associated BF-RhodoLED® lamp systems used in photodynamic therapy procedures. The company also markets dermatological products through physician offices, dermatology clinics, and healthcare providers specializing in skin cancer treatment and chronic skin disorders. Revenue is driven by product sales, recurring treatment usage, and device placements supporting therapy adoption.

The company’s operations are primarily U.S.-focused, although its products originate from technologies developed through historical relationships with Biofrontera AG. Biofrontera Inc. has maintained licensing and supply relationships connected to intellectual property, manufacturing, and regulatory approvals tied to the broader Biofrontera platform. The company’s commercial infrastructure includes specialty pharmaceutical sales operations, reimbursement support capabilities, and physician education initiatives designed to increase adoption of photodynamic therapy treatments in dermatology practices.

Strategic Position & Investments

Biofrontera Inc.’s strategic direction has focused on expanding physician adoption of photodynamic therapy and broadening the clinical usage profile of its dermatology products. Growth initiatives have included expanding sales force coverage, increasing reimbursement support for providers, and pursuing additional FDA-approved indications related to dermatologic oncology and inflammatory skin diseases. The company has also emphasized physician training and treatment workflow integration as part of its commercial expansion strategy.

The company’s investment priorities have centered on dermatology-focused commercialization infrastructure and clinical development opportunities linked to existing approved products. Biofrontera Inc. has maintained strategic ties to technologies and intellectual property associated with Biofrontera AG, while continuing to evaluate opportunities within medical dermatology and photodynamic treatment technologies. Public filings and investor disclosures indicate a continued emphasis on expanding utilization of light-based therapeutic platforms and increasing market penetration in outpatient dermatology practices.

Geographic Footprint

Biofrontera Inc. is headquartered in the United States, with principal commercial operations focused on the U.S. dermatology market. The company’s commercial reach spans dermatology clinics and healthcare systems across multiple U.S. regions, supported by a specialized sales and reimbursement support organization. Its products are marketed primarily to dermatologists treating actinic keratosis and related skin conditions.

Although Biofrontera Inc.’s direct operational footprint is concentrated domestically, its business has international connections through product sourcing, licensing arrangements, and historical affiliations with Germany-based Biofrontera AG. The underlying technologies and regulatory development history of key products have roots in Europe, contributing to the company’s broader international industry relationships and intellectual property framework.

Leadership & Governance

Biofrontera Inc. is governed by a board of directors and executive leadership team focused on commercial dermatology growth, regulatory compliance, and product expansion within the U.S. healthcare market. Leadership strategy has emphasized expanding product utilization, strengthening physician relationships, and improving operational efficiency while managing commercialization costs associated with specialty pharmaceuticals.

Key executives have included:

• Hermann Luebbert – Executive Chairman
• Richard G. Tilton – Chief Executive Officer
• Chris Marschall – Chief Financial Officer
• Patrick F. Rogers – Chief Commercial Officer
• Mara Michel – Chief Operating Officer

The company’s leadership approach has emphasized disciplined commercialization of specialty dermatology therapies, continued support for photodynamic therapy adoption, and expansion of treatment awareness among healthcare providers. Public disclosures and corporate filings indicate a strategic focus on operational execution, reimbursement access, and long-term growth in dermatologic oncology-related therapies.